Medical Professionals Reference (MPR)Seizure Risk Prompts FDA Label Update for Carbidopa/Levodopa Products

FDA now requires seizure warnings on all carbidopa/levodopa products after reviewing 14 cases of vitamin B6 deficiency-linked seizures, including 2 deaths. Patients on levodopa doses exceeding 1,000mg daily face elevated risk, with seizure onset occurring up to 11 years after treatment initiation.

Professional Impact

• Traditional antiseizure medications failed in most reported cases; only vitamin B6 supplementation resolved seizures across 9 patients
• Status epilepticus occurred in some cases, with elevated homocysteine and neuropsychiatric symptoms appearing as early warning signs
• FDA is requiring labeling updates for all carbidopa/levodopa-containing products, including formulations with no reported cases

Action Items

• Check baseline vitamin B6 levels before initiating any carbidopa/levodopa therapy
• Monitor B6 periodically and when neuropsychiatric symptoms or elevated homocysteine emerge
• Recognize that standard antiseizure medications are ineffective for B6 deficiency seizures

More on Seizures